http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106474100-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0d44338a9983e0302c286cb9d319ff9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 |
| filingDate | 2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_685253980351b754f8ecf6867157fabf |
| publicationDate | 2017-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106474100-A |
| titleOfInvention | Application of the Friedolanostanes in preventing and treating hepar damnification medicine is prepared |
| abstract | The present inventor has carried out pharmaceutical research to Friedolanostanes, it was found that Friedolanostanes has protective action, the acute liver to CCl4 induction to have protective action to the acute liver that D amine-galactose amine (D galactosamine, D GalN) is induced.Therefore, Friedolanostanes can be used for preparing the medicine of preventing and treating hepatic injury or hepatitis.Purposes of the Friedolanostanes according to the present invention in treatment hepar damnification medicine is prepared belongs to first public, as framework types belong to brand-new framework types, and which is unexpectedly strong for the therapeutic action activity of hepar damnification, there is no the possibility that any enlightenment is given by other compounds, possess prominent substantive distinguishing features, be simultaneously used for anti-hepar damnification and obviously there is significant progress. |
| priorityDate | 2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.